Breast cancer, Gynaecological cancer, Genitourinary cancer
Dr. Anji Anand is a highly regarded Consultant Clinical Oncologist with over a decade of experience specialising in the treatment of gynaecological and breast cancers. Based at Nottingham University Hospitals NHS Trust, Dr. Anand has been at the forefront of oncology care since her appointment in 2010, offering advanced, personalised treatments to her patients. Her expertise, combined with her commitment to providing patient-centred care, makes her one of the leading oncologists in the Midlands, serving Nottingham, Derby, Lincoln, and beyond.
Specialist Interests and Expertise
Dr. Anand’s clinical expertise spans the comprehensive management of breast and gynaecological cancers, including:
Breast Cancer
Radiotherapy
Chemotherapy
Hormonal and Biological Therapy
Professional Roles and Contributions
Dr. Anand works closely with a multidisciplinary team to ensure that every patient receives thorough and personalised consultations, with a focus on developing effective and tailored treatment plans based on the latest evidence-based practices.
Academic and Professional Achievements
Dr. Anand is a Fellow of the Royal College of Radiologists (FRCR) and a member of:
Her contributions extend beyond clinical practice to include participation in clinical research and the development of advanced treatment protocols. Her commitment to education is reflected in her active role as a mentor and lecturer, sharing her expertise with the next generation of oncologists.
Publications and Research Contributions
Dr. Anji Anand has an extensive portfolio of research contributions and peer-reviewed publications, reflecting her commitment to advancing the field of oncology. Her work spans a variety of topics, including innovative treatments for gynaecological and breast cancers, novel chemotherapy regimens, and the use of targeted therapies. Below is a selection of her notable research and publications:
Peer-Reviewed Publications
- The Nottingham Experience: Topotecan for Relapsed Ovarian Cancer
Anand A, Chan SY;* Clinical Oncology, 2004 Dec; 16(8):543-8
- This study evaluated the use of Topotecan in relapsed ovarian cancer in accordance with the National Institute of Clinical Excellence Guidance (2001).
- External Beam Radiotherapy for Extensive Genital Condyloma Acuminata
Dhadda AS, Anand A, Boynton C, Chan S;* Clinical Oncology, 2008 Feb; 20(1):91-2
- This research explored the role of external beam radiotherapy in selected patients with extensive genital condyloma acuminata.
- Objective Responses to Neo-Adjuvant Carboplatin–Paclitaxel in Ovarian Cancer (ICON8)
Morgan RD, McNeish I, Cook A, James EC, Anand A, et al.;* The Lancet Oncology, 2021 Feb; 22(2):277-288
- This post-hoc exploratory analysis of a Phase III trial assessed neo-adjuvant regimens for ovarian, fallopian tube, or primary peritoneal carcinoma.
- PARAGON Trial: Phase II Study of Anastrozole in Low-Grade Endometrial Stromal Sarcomas
Friedlander M, Benson C, Anand A, et al.;* Gynaecologic Oncology, 2021 April; 161(1):160-165
- This study investigated the efficacy of anastrozole in patients with recurrent estrogen receptor-positive low-grade endometrial stromal sarcomas.
- Cisplatin Chemotherapy and Imbalance in Adult Cancer Survivors
Prayuenyong P, Kasbekar AV, Hall D, Anand A, Baguley D;* Otology and Neurotology, 2021 July; 42(6):e730-e734
- A clinical study examining the imbalance experienced by adult cancer survivors undergoing cisplatin chemotherapy.
Recent and Ongoing Research
- Palbociclib or Ribociclib with Aromatase Inhibitor in ER+/HER2- Advanced Breast Cancer
- Short Communication Submitted to Cancer Treatment and Research Communication Journal, October 2022.
- Co-authored with Prof. Srinivasan Madhusudan and others, this study provides real-world survival evidence for post-menopausal women treated with CDK4/6 inhibitors.
- CDK4/6 Inhibitors in De Novo or Elderly Post-Menopausal ER+/HER2- Advanced Breast Cancers
- Manuscript Submitted to Cancers Journal, October 2023.
- A retrospective study on the effectiveness of CDK4/6 inhibitors in elderly breast cancer patients.
- Induction Chemotherapy Followed by Chemoradiotherapy in Locally Advanced Cervical Cancer
Anand A, Eminowicz G, Vaja S, et al.;* Published in The Lancet, October 2024.
- This international, multicenter Phase III trial evaluated induction chemotherapy in combination with standard chemoradiotherapy for cervical cancer.
- Quality of Life Sub-Study of the GCIG INTERLACE Trial
- Submitted to Lancet Oncology, October 2024.
- Co-authored study examining the quality of life outcomes of induction chemotherapy followed by chemoradiotherapy in cervical cancer patients.
Books and Book Chapters
- Systemic Therapies in Gynaecological Cancers
- Co-authored with Benjamin Masters; *Gynaecological Oncology for the MRCOG,* Cambridge Medicine, 2018.
Dr. Anand’s research has been widely published in prestigious journals such as The Lancet, Gynaecologic Oncology, and Clinical Oncology. Her work not only highlights her expertise in targeted therapies, advanced chemotherapy, and radiotherapy but also establishes her as a trusted authority in oncological research and practice.
Patients and peers alike benefit from Dr. Anand’s dedication to integrating the latest evidence-based treatments into clinical practice, ensuring optimal outcomes for her patients.
Patient-Centred Care
Dr. Anand believes in a holistic approach to cancer care, emphasising patient involvement in treatment planning. She combines compassion with cutting-edge science to ensure the best outcomes for her patients, while her approachable manner fosters trust and comfort during what can be a challenging time.
Why Choose Dr. Anji Anand
Dr. Anand’s expertise in advanced oncology treatments, her leadership in developing innovative protocols like HDR brachytherapy, and her focus on delivering tailored patient care make her a trusted name in cancer care across the Midlands. Patients in Nottingham, Derby, Lincoln, and the wider region benefit from her dedication to providing the highest standards of care.
Appointments
Dr. Anand offers private consultations at GenesisCare Nottingham, ensuring patients have access to cutting-edge diagnostics and treatments in a supportive setting.
Contact GenesisCare Nottingham to schedule your consultation with Dr. Anji Anand and take the first step towards personalised, expert cancer care.
MBBS, MRCP, MSc, FRCR.,
Radiotherapy, Chemotherapy, Hormonal therapy and biological therapy, Cervix cancer, Concurrent chemo-radiotherapy, HDR brachytherapy, Uterine cancers, Intensity modulated radiotherapy, Ovarian cancers, Adjuvant and palliative chemotherapy, VEGF inhibitors, PARP inhibitors, Adjuvant breast radiotherapy, palliative chemotherapy for breast cancers, Palliative radiotherapy for pain control, Endocrine treatment for breast cancers, Monoclonal antibody treatment, Ovarian cancer, Breast radiotherap
English, Hindi, Kannada, Konkani
Initial consultation £150
Brachytherapy is a form of radiotherapy where a sealed radioactive source is placed inside or next to the area requiring treatment. The radioactive source is inserted and transported inside the body using a computer controlled wire driven through small flexible tubes. The proximity of the radioactive source to the treatment site means a high dose of radiation can be delivered whilst limiting the dose to the surrounding tissue
